Redpin Therapeutics Information

Redpin Therapeutics is a privately-held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy. Our science is based on the groundbreaking discovery and development of an ultrapotent ion channel-based chemogenetics platform that enables targeted cell activation or inhibition controlled by low doses of the anti-smoking drug varenicline (CHANTIX®).